Building momentum

Avrobio Inc. parlayed positive clinical data and an aggressive in-licensing strategy into a $60 million series B round that will fund early clinical development of three long-acting lysosomal storage disease candidates.

Cormorant Asset Management and Surveyor Capital led the untranched round, which closed on Feb. 1, and were joined by fellow new investors Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners and existing investors Atlas Venture, SV Health Investors and Clarus...